Opioid Receptor Expression in Colorectal Cancer: A Nested Matched Case-Control Study.

BACKGROUND: There is growing interest in the possible effect of perioperative anesthetic management on the growth and spread of cancer. The impact of perioperative use of opioids on cancer recurrence remains controversial and an assessment cannot yet be established based on current publications. Thi...

Descripción completa

Detalles Bibliográficos
Autores: Belltall, A, Mazzinari, G, Garrido-Cano, I, Giner, F, Mari, AM, Eroles, P, Argente-Navarro, MP, Cata, JP, Diaz-Cambronero, O
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:INCLIVA
Repositorio:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p16638
Acceso en línea:https://incliva.portalinvestigacion.com/publicaciones/16638
Access Level:acceso abierto
Palabra clave:cancer
immunohistochemistry
neoplasm
opioid receptors
perioperative opioid
surgery
tumor
id ES_e9bc91f0651d381f50f0d2ab9fe2b75e
oai_identifier_str oai:incliva.fundanetsuite.com:p16638
network_acronym_str ES
network_name_str España
repository_id_str
spelling Opioid Receptor Expression in Colorectal Cancer: A Nested Matched Case-Control Study.Belltall, AMazzinari, GGarrido-Cano, IGiner, FMari, AMEroles, PArgente-Navarro, MPCata, JPDiaz-Cambronero, Ocancerimmunohistochemistryneoplasmopioid receptorsperioperative opioidsurgerytumorBACKGROUND: There is growing interest in the possible effect of perioperative anesthetic management on the growth and spread of cancer. The impact of perioperative use of opioids on cancer recurrence remains controversial and an assessment cannot yet be established based on current publications. This study aimed to assess the differential expression of opioid receptors between healthy and tumor tissues in patients with stage II and III colorectal cancer undergoing elective surgery by immunohistochemistry (IHC). METHODS: Propensity-score matched case-control study nested in a retrospective cohort of patients with stage II or III colorectal. The primary endpoint was the difference in µ-opioid receptor (MOR) expression measured by IHC between tumor and healthy tissue in subject with or without recurrence. Secondary endpoints were to evaluate the differences in Opioid Growth Factor Receptor (OGFR), cyclic adenosine monophosphate (cAMP) production and protein kinase A (PKA) in the matched sample and from a from samples of colorectal cancer stored in the Cancer Genome Atlas (TCGA) and Genotype Tissue Expression Project (GTEx). RESULTS: There was a significant difference in MOR receptor (median 3 [intequartile range IQR: 1-3] and 0 [IQR: 0-2], P<0.001) and OGFR receptor (median 6 [IQR: 5-6] and 2 [IQR: 1-2], P<0.001) in tumor and control tissue respectively. However, there were no significant differences in cAMP nor PKA expression between both types of tissues and in expression in any of the analyzed variables by recurrence status. The MOR and OGFR expression data from TCGA database were similar to our sample size data with lower expression of MOR and higher expression of OGFR in tumoural samples with a skewed distribution for MOR expression in tumor tissue both in patients with and without recurrence. CONCLUSION: In patients with stage II and III colorectal cancer, overall expression of MOR and OGFR was significantly increased but was not different between previously matched patients with or without recurrence. No differences were found in the analyzed metabolic pathway of cAMP-PKA: These results were confirmed by an in silico analysis of samples from the TCGA-GTEx database.FRONTIERS MEDIA SA2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/16638Frontiers in OncologyISSN: 2234943Xreponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAInglésinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p166382026-06-07T16:35:31Z
dc.title.none.fl_str_mv Opioid Receptor Expression in Colorectal Cancer: A Nested Matched Case-Control Study.
title Opioid Receptor Expression in Colorectal Cancer: A Nested Matched Case-Control Study.
spellingShingle Opioid Receptor Expression in Colorectal Cancer: A Nested Matched Case-Control Study.
Belltall, A
cancer
immunohistochemistry
neoplasm
opioid receptors
perioperative opioid
surgery
tumor
title_short Opioid Receptor Expression in Colorectal Cancer: A Nested Matched Case-Control Study.
title_full Opioid Receptor Expression in Colorectal Cancer: A Nested Matched Case-Control Study.
title_fullStr Opioid Receptor Expression in Colorectal Cancer: A Nested Matched Case-Control Study.
title_full_unstemmed Opioid Receptor Expression in Colorectal Cancer: A Nested Matched Case-Control Study.
title_sort Opioid Receptor Expression in Colorectal Cancer: A Nested Matched Case-Control Study.
dc.creator.none.fl_str_mv Belltall, A
Mazzinari, G
Garrido-Cano, I
Giner, F
Mari, AM
Eroles, P
Argente-Navarro, MP
Cata, JP
Diaz-Cambronero, O
author Belltall, A
author_facet Belltall, A
Mazzinari, G
Garrido-Cano, I
Giner, F
Mari, AM
Eroles, P
Argente-Navarro, MP
Cata, JP
Diaz-Cambronero, O
author_role author
author2 Mazzinari, G
Garrido-Cano, I
Giner, F
Mari, AM
Eroles, P
Argente-Navarro, MP
Cata, JP
Diaz-Cambronero, O
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv cancer
immunohistochemistry
neoplasm
opioid receptors
perioperative opioid
surgery
tumor
topic cancer
immunohistochemistry
neoplasm
opioid receptors
perioperative opioid
surgery
tumor
description BACKGROUND: There is growing interest in the possible effect of perioperative anesthetic management on the growth and spread of cancer. The impact of perioperative use of opioids on cancer recurrence remains controversial and an assessment cannot yet be established based on current publications. This study aimed to assess the differential expression of opioid receptors between healthy and tumor tissues in patients with stage II and III colorectal cancer undergoing elective surgery by immunohistochemistry (IHC). METHODS: Propensity-score matched case-control study nested in a retrospective cohort of patients with stage II or III colorectal. The primary endpoint was the difference in µ-opioid receptor (MOR) expression measured by IHC between tumor and healthy tissue in subject with or without recurrence. Secondary endpoints were to evaluate the differences in Opioid Growth Factor Receptor (OGFR), cyclic adenosine monophosphate (cAMP) production and protein kinase A (PKA) in the matched sample and from a from samples of colorectal cancer stored in the Cancer Genome Atlas (TCGA) and Genotype Tissue Expression Project (GTEx). RESULTS: There was a significant difference in MOR receptor (median 3 [intequartile range IQR: 1-3] and 0 [IQR: 0-2], P<0.001) and OGFR receptor (median 6 [IQR: 5-6] and 2 [IQR: 1-2], P<0.001) in tumor and control tissue respectively. However, there were no significant differences in cAMP nor PKA expression between both types of tissues and in expression in any of the analyzed variables by recurrence status. The MOR and OGFR expression data from TCGA database were similar to our sample size data with lower expression of MOR and higher expression of OGFR in tumoural samples with a skewed distribution for MOR expression in tumor tissue both in patients with and without recurrence. CONCLUSION: In patients with stage II and III colorectal cancer, overall expression of MOR and OGFR was significantly increased but was not different between previously matched patients with or without recurrence. No differences were found in the analyzed metabolic pathway of cAMP-PKA: These results were confirmed by an in silico analysis of samples from the TCGA-GTEx database.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://incliva.portalinvestigacion.com/publicaciones/16638
url https://incliva.portalinvestigacion.com/publicaciones/16638
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv FRONTIERS MEDIA SA
publisher.none.fl_str_mv FRONTIERS MEDIA SA
dc.source.none.fl_str_mv Frontiers in Oncology
ISSN: 2234943X
reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname:INCLIVA
instname_str INCLIVA
reponame_str r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423077692014592
score 15,812455

Similares en LA Referencia